Fight Against Superbugs Hinges on Struggling Small Biotechs

Gemmell covers findings from the new report -- part of the Antimicrobial Resistance Benchmark research programme -- which looks into the crucial role that small- and medium-sized medicine makers play in providing the world's antibiotics. While these companies lead 75% of research and development efforts for new, desperately needed antibiotics that have lifesaving potential in the face of growing antimicrobial resistance, small companies are chronically under-funded and at risk of bankruptcy. 

Jayasree K. Iyer, Executive Director for the Access to Medicine Foundation, is quoted in the article: "The pandemic of drug-resistant infections will pose a bigger global health emergency than Covid-19, and it’s a silent pandemic that is already growing."

Click here to read the full article.